Literature DB >> 29796702

[Small renal cell carcinoma-active surveillance and ablation].

J J Wendler1, R Damm2, U-B Liehr3, T Brunner4, M Pech2, M Schostak3.   

Abstract

The incidence of renal cell carcinoma has been rising for years. At the same time there is an increasing prevalence of chronic renal failure with subsequent higher morbidity and shorter life expectancy in those affected. In the last decades the gold standard has thus shifted from radical to partial nephrectomy or tumor enucleation. A treatment alternative can be advantageous for selected patients with high morbidity and an increased risk of complications in anesthesia or surgery. Active surveillance represents a controlled delay in the initiation of treatment with a curative intention. Percutaneous radiofrequency ablation and laparoscopic cryoablation are currently the most commonly used treatment alternatives. Newer ablation procedures, such as high-intensity focused ultrasound, irreversible electroporation, microwave ablation, stereotactic ablative radiotherapy and high-dose brachytherapy have a high potential in some cases but are still considered experimental for the treatment.

Entities:  

Keywords:  Ablation; Active surveillance; Focal therapy; Renal mass lesion; Small renal tumor

Mesh:

Year:  2018        PMID: 29796702     DOI: 10.1007/s00120-018-0677-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  48 in total

1.  ABLATE: a renal ablation planning algorithm.

Authors:  Grant D Schmit; A Nicholas Kurup; Adam J Weisbrod; R Houston Thompson; Stephen A Boorjian; C Thomas Wass; Matthew R Callstrom; Thomas D Atwell
Journal:  AJR Am J Roentgenol       Date:  2014-04       Impact factor: 3.959

2.  Evaluation of Tumor Pseudocapsule Status and its Prognostic Significance in Renal Cell Carcinoma.

Authors:  Wei Xi; Jiajun Wang; Li Liu; Ying Xiong; Yang Qu; Zhiyuan Lin; Xiang Chen; Zewei Wang; Jiejie Xu; Jianming Guo
Journal:  J Urol       Date:  2017-11-08       Impact factor: 7.450

3.  Radiofrequency ablation of small renal cell carcinomas using multitined expandable electrodes: preliminary experience.

Authors:  Timothy W I Clark; Bruce Malkowicz; S William Stavropoulos; Richard Sanchez; Michael C Soulen; Maxim Itkin; Aalpen Patel; Jeffrey I Mondschein; A J Wein
Journal:  J Vasc Interv Radiol       Date:  2006-03       Impact factor: 3.464

4.  Renal Mass and Localized Renal Cancer: AUA Guideline.

Authors:  Steven Campbell; Robert G Uzzo; Mohamad E Allaf; Eric B Bass; Jeffrey A Cadeddu; Anthony Chang; Peter E Clark; Brian J Davis; Ithaar H Derweesh; Leo Giambarresi; Debra A Gervais; Susie L Hu; Brian R Lane; Bradley C Leibovich; Philip M Pierorazio
Journal:  J Urol       Date:  2017-05-04       Impact factor: 7.450

5.  Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study.

Authors:  J J Wendler; M Pech; J Köllermann; B Friebe; S Siedentopf; S Blaschke; D Schindele; M Porsch; D Baumunk; J Jürgens; F Fischbach; J Ricke; M Schostak; M Böhm; U B Liehr
Journal:  Cardiovasc Intervent Radiol       Date:  2017-09-19       Impact factor: 2.740

6.  Durable oncologic outcomes after radiofrequency ablation: experience from treating 243 small renal masses over 7.5 years.

Authors:  Chad R Tracy; Jay D Raman; Chester Donnally; Clayton K Trimmer; Jeffrey A Cadeddu
Journal:  Cancer       Date:  2010-07-01       Impact factor: 6.860

7.  Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older.

Authors:  Brian R Lane; Robert Abouassaly; Tianming Gao; Christopher J Weight; Adrian V Hernandez; Benjamin T Larson; Jihad H Kaouk; Inderbir S Gill; Steven C Campbell
Journal:  Cancer       Date:  2010-07-01       Impact factor: 6.860

8.  Metastatic renal cell carcinoma risk according to tumor size.

Authors:  R Houston Thompson; Jennifer R Hill; Yuriy Babayev; Angel Cronin; Matt Kaag; Shilajit Kundu; Melanie Bernstein; Jonathan Coleman; Guido Dalbagni; Karim Touijer; Paul Russo
Journal:  J Urol       Date:  2009-05-17       Impact factor: 7.450

9.  Solid renal tumors: an analysis of pathological features related to tumor size.

Authors:  Igor Frank; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

10.  Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours.

Authors:  Tze M Wah; Henry C Irving; Walter Gregory; Jon Cartledge; Adrian D Joyce; Peter J Selby
Journal:  BJU Int       Date:  2013-10-22       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.